Introduction Long-term efficacy of anti-PD1 therapy and the need for a consolidation with
allogenic haematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients …

Introduction: Autologous stem cell transplants (ASCT) are standard of care for patients with
primary refractory or recurrent Hodgkin lymphoma (HL). While transplant results in cure for …

Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in
approximately one-third of the responding patients, the disease relapses following …

Autologous stem cell transplantation (ASCT) can be curative for patients with
relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 …

Clinical trials have shown that nivolumab has remarkable activity against relapsed/refractory
classical Hodgkin lymphoma (cHL). However, the role of allogeneic hematopoietic stem cell …

Previous studies have reported that an antibody that blocks programmed cell death 1 (PD-1)
has therapeutic activity in patients with refractory/relapsed Hodgkin lymphoma (HL) …

Purpose Genetic alterations causing overexpression of programmed death-1 ligands are
near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 …

This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with
ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to …

Although autologous stem cell transplantation (auto-HCT) is the standard of care for patients
with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL), there is still a significant …

BACKGROUND: It has been recently shown that nivolumab, a programmed death 1 (PD-1)
blocking antibody, had substantial therapeutic activity and an acceptable safety profile in …